Answers are grounded in this paper and cite their sources.
Case report uncovered severe complications related to transarterial microembolization, highlighting risks in patient selection.
Transarterial microembolization (TAME) has gained recognition as a minimally invasive treatment for chronic musculoskeletal pain, demonstrating significant efficacy with a favorable safety profile ( 1, 2). However, complications remain underreported. This case report describes the first documented severe adverse event in a patient with a chronic venous ulcer undergoing TAME for a micro arteriovenous fistula (AVF). The patient developed significant complications, including extensive leg swelling, skin changes, and cellulitis requiring prolonged inpatient care. These findings highlight the importance of patient selection and embolic agent considerations to mitigate potential risks associated with TAME.
No takes yet. Share an insight, caveat, or question.
Boonlorm et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: